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Abstract: 
Our answer to the question posed in the title is negative. This intentionally provocative note discusses the issue of sample size in 
microarray studies from several angles. We suggest that the current view of microarrays as no more than a screening tool be 
changed and small sample studies no longer be considered appropriate.  
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Background: 
As obvious from recent literature, in the decade since the 
advent of microarray technology, the enthusiasm about this 
technology has substantially subsided. The titles of papers 
like “An Array of Problems [1] or “Getting the Noise out of 
Gene Arrays” [2] published in high profile journals speak for 
themselves. A growing number of such publications reflects 
a frustration among biologists who spend too much effort 
and money pursuing false leads while missing many 
important findings. Is it the microarray technology or the 
way it has been used that is to blame for the current attitude 
towards the as yet emerging methodologies for the 
generation and analysis of high throughput data in genomics 
and proteomics?  
 
Notwithstanding the fact that contemporary microarray 
technology still calls for substantial improvements in both 
the quality of measurements and accuracy of probe set 
definitions, this powerful technology provides a rich source 
of multidimensional information on the functioning of the 
whole genome machinery at the level of transcription. 
Nonetheless, it is typically employed as a simplistic 
screening tool with a focus on individual gene profiling. 
Unfortunately, even this limited goal cannot be achieved 
with currently practiced sample sizes for the following two 
reasons. First, all multiple testing procedures are very 
unstable in the presence of correlations between gene 
expression levels, which is the main factor causing instability 
of gene lists. By and large the more liberal the procedure, the 
more unstable the adjusted p-values.  [3, 4] This effect is 
exacerbated in small samples. Therefore, the actual number 
of false discoveries is not well controlled even if strong 
control is guaranteed in terms of expected values. Second, 
follow-up confirmatory studies can handle only Type 1 errors 
while a lack of power is a much more serious problem. When 
the sample size is small and the number of tests is large, the 
power of multiple testing procedures is extremely poor, so 
we tend to report only unusually strong effects while missing 
an uncontrollable number of biologically significant findings.  
 
It is still quite common in biological publications to report 
microarray data on a small number of subjects. All papers 
claiming “consistency” or, conversely, “inconsistency" of 
the results produced by different microarray platforms draw 
their conclusions from just 3-6 arrays (subjects) per group. 
We would like to emphasize that it is not the technical 
noise that represents the main hurdle, it is the biological 
variability that calls for larger samples. A recently 
published report of the MicroArray Quality Control 
(MAQC) Consortium [5] provides direct measurements of 
the technical noise specific for the Affymetrix platform in 
the absence of biological variability. We estimated standard 
deviations of log-transformed expression levels associated 
with all genes (probe sets) from technical replicates 
produced by the MAQC study. They appear to be 
symmetrically distributed across genes. The resultant 
average (over genes) equaling 0.11 is at least three times as 
small as a typical minimal (let alone the mean) standard 
deviation in the presence of biological variability. A log-
additive random noise as small as this exerts almost no 
effect on the results of statistical analysis in general and 
estimates of correlation coefficients in gene pairs in 
particular. This is definitely good albeit belated news to the 
scientific community. However, the inter-subject variability 
is beyond the control of the manufacturer and can be 
accounted for only through sampling from a general 
population of subjects. 
 
The use of small samples significantly diminishes the 
utility of microarray analysis. The following simplistic 
experiment with real biological data illustrates this point. 
We used microarray data reporting expression levels of 
12558 probe sets in two groups of patients with different 
types of childhood leukemia (Hyperdip and TALL) 
identified through the St. Jude Children’s Research 
Hospital Database. [6] There were 88 and 45 subjects in 
these groups, respectively. To mimic a small-sample 
setting, five hundred (B=500) pseudo-independent 
subsamples of n=5 arrays were drawn repeatedly without 
replacement from each group. Differentially expressed 
genes were selected from each pair of subsamples by a t-
test with Bonferroni adjustment at a nominal level of the 
family-wise error rate of 0.05. This experiment resulted in 
the mean number of rejections equaling 3.63, while the 
standard deviation was equal to 7.69, indicating a very high 
variability of the results of testing.  
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such as partially known pathways, for prioritization of 
candidate genes. However, the current biological knowledge 
is still limited and inaccurate. This way of validation serves 
as a reasonable underpinning for statistical inference (limited 
to Type 1 errors) but not a rigorous method. When the 
biologist has some preliminary idea of what specific set of 
genes to look at, the significance analysis becomes 
confirmatory, thereby dramatically reducing the magnitude 
of multiple testing problems. This is the basic idea behind the 
Gene Set Enrichment Analysis (see [7] and references 
therein). However, this approach is limited to pre-defined 
gene sets and does not offer an alternative to the much 
needed exploratory tools.  
 
The problem of differential expression is neither unique nor 
the most important one in the analysis of microarrays. The 
magnitude of differential expression does not necessarily 
indicate biological significance, so that the price for non-
discoveries is difficult to assess. By limiting the use of 
microarrays to screening purposes, we do not unveil the true 
potential of this resourceful technology. It is imperative for 
statisticians to be able to extract more information from 
microarray data in order to prioritize genes in a more 
meaningful way. In particular, additional information can be 
provided by gene pairs rather than individual genes. It is 
noteworthy that recent years have seen a growing interest in 
correlations between gene expression levels in statistical 
methodologies for microarray analysis ([8-11] and many 
others). We suggest that the focus of future efforts be 
switched to the formation of a vector of different attributes 
that can be assigned to each gene in order to provide more 
information for gene prioritization beyond changes in the 
marginal distribution across phenotypes. The components of 
this vector might be adjusted p-values resulting from various 
statistical tests, prevalence of a specific type of correlation 
with other genes, relevance to the known pathways, etc. This 
will allow the investigator to initially increase the target set 
of genes by including more biologically meaningful features 
and then to narrow it down by putting such pieces of 
information together and generating a final output in an 
automated fashion. Such an endeavor is feasible only if 
larger samples become more readily available.  
 
Statisticians have never insisted on increasing the sample 
size vigorously enough. Instead, many attempts have been 
made to overcome the sample size and cost limitations by 
means of mathematics. Such methodological endeavors 
invariably resort to the idea of pooling the information on 
gene expression across genes. While some of them are quite 
elegant, it has become clear that the actual correlation 
structure of microarray data is a barrier to their real world 
applications and this barrier seems to be insurmountable at 
this point in time. We have contributed to the discussion of 
this issue with several publications [12-14], providing 
evidence that the variability of the results of testing based on 
such methods may be extremely high. This variability 
manifests itself in the number of rejected hypotheses and 
estimated values of the false discovery rate. As a 
consequence, one may declare 1500 genes differentially 
expressed while there are none. [13] It is correlations 
between gene expression signals that cause this kind of 
instability because they are not only strong but also long-
ranged, involving thousands and sometimes tens of 
thousands of genes that form pairs with each particular gene. 
[10, 15] The long-range strong correlation prevails in a huge 
proportion of randomly selected genes. Pooling strategies 
such as the Empirical Bayes method may work for cluster 
dependent data [16],  but not in the presence of long-range 
dependencies.  
 
Unfortunately, there is no theoretical way to justify the 
required minimal sample size. We share the opinion of Yang 
and Speed [17] that power calculations are of little utility in 
microarray studies. The main point is that microarray 
analysis is exploratory (not confirmatory!) by nature and the 
most essential components of the standard power 
calculations (such as preliminary information on the 
expected effect sizes, variability, and the number of affected 
genes) are absent. [17]  
 
It is our strong conviction that small sample sizes in 
microarray studies are a serious handicap to the progress of 
modern genomics. However trivial the above statement may 
sound, its importance remains unrealized by practitioners. 
We have expressed this concern before in connection with 
the MAQC study. [18] At the same time, there is a growing 
understanding of the importance of replication in microarray 
experiments and many large databases are being created in 
different areas of biomedical research. Now we are facing a 
new era in this field of data analysis, an era of large data sets. 
The future of microarray technology hinges on our ability to 
respond to this challenge. 
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